Australian Journal of General Practice
MBBS, FRACP, Endocrinologist, Department of Endocrinology, Princess Alexandra Hospital, Woolloongabba, Qld; Endocrinology Research Fellow, The University of Queensland Diamantina Institute, Translational Research Institute, Qld
Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.